Geron Corporation

Geron Corporation is a late-stage clinical biopharmaceutical company focused on developing and potentially commercializing a telomerase inhibitor, imetelstat, for hematologic myeloid malignancies. The company's prior clinical trials have shown strong evidence of disease-modifying activity from imetelstat treatment. In addition to its core oncology and human embryonic stem cell programs, Geron also utilizes its intellectual property and resources to develop research and development products and services based on nuclear transfer. The company was founded in 1990 and is headquartered in Menlo Park, Calif., with a subsidiary in Edinburgh, Scotland. Geron's common shares trade on the NASDAQ under the ticker symbol GERN.